Beatrice Low

Associate
Singapore
email hidden; JavaScript is required
Beatrice Low

Beatrice’s practice focuses on corporate and commercial transactions. She advises clients on a broad spectrum of matters, including share and asset acquisitions, joint ventures, private equity investments and corporate restructurings.

Prior to joining Helmsman, Beatrice served as in-house counsel at a government agency. She also trained and practiced at one of the largest law firms in Singapore, where she was actively involved in cross-border M&A transactions, venture capital financing rounds, and corporate governance matters. This commercial exposure enables Beatrice to provide clients with practical and business-oriented solutions.

Beatrice has represented  a diverse array of clients, including multinational corporations, publicly listed companies, financial institutions, private equity firms, and start-ups across sectors such as real estate, technology, telecommunications, pharmaceuticals, and healthcare. She co-authored Chapter F: Shares, Debentures and Charges in Woon’s Corporations Law, published by LexisNexis. 

She is an Advocate and Solicitor of the Supreme Court of Singapore and holds an LLB (Hons) from The Australian National University. 


Experience / Representative Matters

Corporate Transactions

Acted as Singapore counsel as part of a multi-disciplinary team to Pfizer Inc. and Pfizer Investment Enterprises Pte. Ltd. in the fourth-largest US bond sale ever at US$31 billion. 

Acted as counsel for a group of shareholders of the Singapore Women’s & Children’s Medical Group in a sale of a 60% stake of each of their companies to Foundation Healthcare Holdings Pte. Ltd. (“FHH”). FHH is a purpose-built tech-enabled healthcare platform headquartered in Singapore, and is majority owned by SeaTown Private Capital Master Fund, a private equity fund managed by SeaTown Holdings. As at completion of the wider transaction, FHH consisted of more than 50 private specialists spanning 13 medical specialties, has an estimated pro-forma revenue of over S$130 million, and is one of the largest healthcare groups in Singapore. 

Acted as counsel to a local venture capital company in its Series Seed investment into a biotechnology start-up which is in the business of research and experimental development of a non-viral gene delivery platform and manufacturing processes that enable programming and production of precision engineered cells for solid tumour treatment and regenerative medicine. 

Acted as Singapore counsel for StarHub Ltd in its acquisition of a majority stake in each of HKBN JOS (Singapore) Pte. Ltd. and HKBN JOS (Malaysia) Sdn. Bhd. for an aggregate consideration of approximately S$15 million. 

Areas of Expertise

Corporate

Corporate, Mergers & Acquisitions

No two businesses are alike. Each is built on its own spark, shaped by its journey, and driven by unique ambitions.

Read more
Corporate banking and finance banner

Banking and Finance

Access to financing is vital for businesses to thrive. 

Read more